Summit Therapeutics: Ivonescimab Shows Survival Benefit vs Keytruda

What happened

Summit Therapeutics Inc. said its drug ivonescimab improved overall survival in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) compared with Merck's Keytruda (pembrolizumab) in the Phase III HARMONi-2 study. The company announced the positive results in a press release on September 4, 2026.

The stock jumped 17.33% to close at $17.13, up from the previous close of $14.60, according to price data. Barron's reported shares rose over 12% intraday, while other outlets noted gains of 19.5% to 27%.

The study was conducted by Akeso, Summit's partner, in China. Summit's press release, also carried by Yahoo Finance and Kalkine Media, did not disclose detailed survival numbers, only stating the benefit was 'statistically significant.'

Why it matters

Overall survival is the most definitive endpoint in cancer trials because it measures whether patients actually live longer, not just whether tumors shrink or progression is delayed. A statistically significant OS benefit is the strongest evidence a drug works and can support regulatory approval and change standard of care.

Ivonescimab is being developed as a potential challenger to Keytruda, one of the world's best-selling drugs. The HARMONi-2 result suggests ivonescimab may be more effective in this patient group, which could be significant for Summit, a mid-cap biotech with no approved products and zero revenue as of 2024.

Barron's noted the head-to-head comparison with Keytruda is central to investor interest. Summit's U.S. approval application for ivonescimab has a November deadline, according to StockTitan.

What this means

This was a company announcement, not an SEC filing. Summit issued a press release, which is how public companies disclose major clinical trial results outside of regulatory filings. The release was confirmed by multiple financial news outlets, including RTTNews, Barron's, and Yahoo Finance.

The trial, HARMONi-2, is a Phase III study, meaning it is a late-stage trial designed to prove a drug's efficacy and safety in a large patient group. The name 'HARMONi-2' is specific to this trial; the drug ivonescimab is a bispecific antibody that targets both PD-1 and VEGF, pathways that help cancer evade the immune system.

Pembrolizumab, sold as Keytruda, is a PD-1 inhibitor that has been a standard first-line treatment for NSCLC. The comparison here is 'monotherapy' — each drug given alone, not in combination with chemotherapy. Only patients with PD-L1-positive tumors were included, a biomarker that predicts response to these drugs.

The results are from a trial run entirely in China. That means the data may not automatically support approval in the U.S. or Europe; regulators often require a global or regional confirmatory trial. Summit and Akeso have separate rights: Akeso has rights in China, Summit has rights elsewhere, including the U.S.

With no revenue, Summit is a development-stage company. Positive clinical data can be its main value driver. The stock rise reflects investor belief that the OS benefit increases the drug's chance of approval and commercial success, but the full data and regulatory review are still ahead.